David Pyott's Trading History
| TARSTarsus Pharmaceuticals | Sep 17, 2026 | Director | Uninformative Buy | 15.72K | $716.69K | |
| ALNYAlnylam Pharma | Jun 03, 2026 | Director | Uninformative Buy | 1.13M | $4.86M | |
| BMRNBioMarin Pharmaceutical | May 23, 2024 | Director | Uninformative Buy | ― | $2.91M | |
| AVYAvery Dennison | Apr 24, 2020 | Director | Uninformative Buy | 152.09K | $3.40M | |
| AGNAllergan | Mar 19, 2015 | ― | Uninformative Sell | ― | $0.00 | |
| EWEdwards Lifesciences | May 13, 2014 | Director | Uninformative Buy | ― | $4.93M | |
| PLRXPliant Therapeutics | ― | Director | ― | ― |
You May Also Like
David Pyott insider profile FAQ
What is the percentage of profitable transactions made by David Pyott?
The percentage of profitable transactions made by David Pyott is 46%.
What is the average return per transaction made by David Pyott?
The average return per transaction made by David Pyott is 13.70%.
What stocks does David Pyott hold?
David Pyott holds: TARS, AGN, ALNY, BMRN, PLRX, AVY, EW stocks.
What was David Pyott’s latest transaction?
David Pyott’s latest transaction was an Uninformative Buy of $15.72K.
What was David Pyott's most profitable transaction?
David Pyott’s most profitable transaction was an Informative Buy of ALNY stock on October 14, 2016. The return on the trade was 248.20%.
What is David Pyott's role in Tarsus Pharmaceuticals?
David Pyott's role in Tarsus Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.